Amendment One to Licence of TechnologyLicence of Technology • May 9th, 2018 • Achieve Life Sciences, Inc. • In vitro & in vivo diagnostic substances
This Amendment One to Licence of Technology Agreement (this “Amendment”) is entered into as of this 22nd day of January 2018 (the “Amendment Effective Date”), by and between The University of Bristol, Senate House, Tyndall Avenue, Bristol, BS8 1TH, England (“Licensor”) and Achieve Life Sciences, Inc., a Delaware corporation having its principal place of business at 19820 North Creek Parkway, Suite 201, Bothell, Washington, 98011 (“Licensee”). Licensor and Licensee are each referred to herein a “Party” or, collectively, as the “Parties.” Capitalized terms used herein and not defined shall have the meaning assigned to them in the Agreement.
Amendment One to Licence of TechnologyLicence of Technology • May 23rd, 2018 • Achieve Life Sciences, Inc. • In vitro & in vivo diagnostic substances
This Amendment One to Licence of Technology Agreement (this “Amendment”) is entered into as of this 22nd day of January 2018 (the “Amendment Effective Date”), by and between The University of Bristol, Senate House, Tyndall Avenue, Bristol, BS8 1TH, England (“Licensor”) and Achieve Life Sciences, Inc., a Delaware corporation having its principal place of business at 19820 North Creek Parkway, Suite 201, Bothell, Washington, 98011 (“Licensee”). Licensor and Licensee are each referred to herein a “Party” or, collectively, as the “Parties.” Capitalized terms used herein and not defined shall have the meaning assigned to them in the Agreement.
DATED 21 January 2002 LICENCE OF TECHNOLOGYLicence of Technology • July 30th, 2004 • Cambridge Display Technology, Inc.
CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED FROM THIS DOCUMENT. SUCH OMISSIONS ARE NOTED BY “[**]”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION.
DATED 21 January 2002 LICENCE OF TECHNOLOGYLicence of Technology • December 15th, 2004 • Cambridge Display Technology, Inc. • Semiconductors & related devices
CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED FROM THIS DOCUMENT. SUCH OMISSIONS ARE NOTED BY “[**]”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION.
DATED 12th October 2017Licence of Technology • April 3rd, 2018 • Nightstar Therapeutics PLC • Biological products, (no disgnostic substances)
• Licensee is a private biopharmaceutical company focused on the development of therapies for inherited retinal dystrophies.
